Key indicators: single-crystal X-ray study; T = 296 K; mean (C-C) = 0.006 Å; R factor = 0.035; wR factor = 0.100; data-to-parameter ratio = 7.2.
In the crystal structure of the title compound [systematic name: 2-(4b-fluoro-5-hydroxy-4a,6a,8,8-tetramethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-7,9-dioxapentaleno[2,1-a] phenanthren-6b-yl)-2-oxoethyl acetate], C 26 H 33 FO 7 , the molecules are connected by intermolecular O-HÁ Á ÁO hydrogen bonds into an infinite supramolecular chain along the b axis. The molecular framework consists of five condensed rings, including three six-membered rings and two five-membered rings. The cyclohexa-2,5-dienone ring is nearly planar [maximum deviation = 0.013 (3) Å ], while the cyclohexane rings adopt chair conformations. The two fivemembered rings, viz. cyclopentane and 1,3-dioxolane, display envelope conformations.
Related literature
For applications of triamcinolone acetonide in medicine, see: Barnes (1998); Buttgereit (2000) ; Uckermann et al. (2005) Table 1 Hydrogen-bond geometry (Å , ). 
Comment
The glucocorticoid triamcinolone acetonide is clinically used for the treatment of suppression of inflammation in chronic inflammatory diseases such as asthma, rheumatiod arthritis, inflammatory bowel disease and autoimmune diseases (Barnes, 1998; Buttgereit, 2000; Uckermann et al., 2005) . Triamcinolone acetonide acetate is another derivatives of triamcinolone, which has been used in therapy for several decades. Despite its great importance, no crystal structures of the title compound has been reported. But crystal structure of it's analogue compounds, triamcinolone diacetate chloroform solvate and triamcinole acetonide methanol solvate have been reported (Suitchlmezian et al., 2006 & Jess et al., 2006 . In the title compound, the bond lengths and angles are in agreement with those reported for other triamcinolone derivatives (Suitchlmezian et al., 2006; Jess et al., 2006) . and are within the expected ranges. The molecular framework consists of five condensed rings, including three six-membered rings and two five-membered rings. Atom O1 is coplanar with cyclohexa-1,4-diene ring (C8-C9-C10-C11-C12-C13), which is planar. Two central six-membered rings (C5-C6-C7-C8-C13-C14) and (C4-C5-C14-C15-C16-C17) are in chair conformation. Two five-membered rings display twisted envelope conformations. The respective r.m.s. deviations for four atoms C1/C2/C3/C17 and C1/C2/O6/O7 are 0.0359 Å, 0.0225Å respectively. The fifth atoms C4, C22 deviate from the above planes by 0.688 (4) Å, 0.458 (4)Å respectively. Hydroxy group and one of the carboxyl O atom are involved in the hydrogen-bonded network. Atom O2 from hydroxy group in the molecule at (x,y,z) act as hydrogen bond donor, to O1 atom of carboxyl group in the molecule (2 -x,-1/2 + y,2 -z). Crystal packing is influenced by this intermolecular hydrogen bond interaction that links the molecules into a chain propagating along b axis.
Experimental
The crude product of the title compound was supplied by Zhejiang Xianju Pharmaceutical Co., LTD. It was recrystallized from methanol solution, giving single crystals suitable for X-ray diffraction.
Refinement
H atoms were placed in calculated positions with C-H = 0.93-0.98 and O-H = 0.82 Å, and included in the refinement in riding model with U iso (H) = 1.2U eq or 1.5U eq (carrier atom). -5-hydroxy-4a,6a,8,8-tetramethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-7,9-dioxa- 
